Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,569 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control regimen Clear all

Conditions: Post-surgical Pain
Interventions: CA-008, Placebo, Ketorolac, Acetaminophen, Oxycodone, Bupivacaine Hydrochloride; Drug
Lead sponsor: Concentric Analgesics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Pasadena, California • Pasadena, Maryland • Houston, Texas

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate, Histamine base; Biological
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 28
States / cities: Oxford, Alabama • Stockbridge, Georgia • Normal, Illinois + 22 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Placebo, Ocrelizumab, Avonex; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2023
U.S. locations: 26
States / cities: Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more

Conditions: Venous Leg Ulcer
Interventions: EpiFix, Compression Therapy; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Boca Raton, Florida • Framingham, Massachusetts • Tulsa, Oklahoma + 2 more

Conditions: Achilles Tendon Rupture
Interventions: Achilles tendon repair; Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: Not listed
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Stress Urinary Incontinence, Pelvic Floor Disorders
Interventions: Pelex Upp, Pelvic Floor Physical Therapy; Device · Behavioral
Lead sponsor: Pelex; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Little Neck, New York

Conditions: Glycogen Storage Disease Type IA
Interventions: DTX401, Placebo, Oral prednisolone, Placebo for oral prednisolone; Genetic · Other · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 8 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Orange, California • Aurora, Colorado • Farmington, Connecticut + 6 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: New York, New York • Seattle, Washington

Conditions: COPD, Acute Respiratory Failure
Interventions: Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Cataract
Interventions: Dexycu intracameral dexamethasone, Prednisolone Acetate; Drug
Lead sponsor: Research Insight LLC; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Laguna Hills, California • Garden City, New York

Conditions: Microbiota
Interventions: OTC Eczema Moisturizer Regimen, Cosmetic Moisturizer Regimen; Drug · Other
Lead sponsor: Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.; Industry
Eligibility: 16 Years to 50 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Colorado Springs, Colorado • Richardson, Texas

Conditions: Thrombotic Microangiopathy
Interventions: Ravulizumab, Placebo, Best supportive care; Biological · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Tampa, Florida • Grosse Pointe Farms, Michigan • Durham, North Carolina + 2 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Benralizumab, Placebo and Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more

Conditions: Hypercholesterolemia
Interventions: Praluent (Alirocumab), Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 2,176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 73
States / cities: Auburn, Alabama • Birmingham, Alabama • Mobile, Alabama + 63 more

Conditions: Stroke
Interventions: Aggrenox, Clopidogrel placebo, Micardis, Aggrenox placebo, Clopidogrel, Micardis placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 50 Years and older
Enrollment: 20,332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 204
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 160 more

Conditions: Community-acquired Pneumonia
Interventions: Heparin; Drug
Lead sponsor: University of Manitoba; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 6
States / cities: Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more

Conditions: Smoking Cessation
Interventions: UP-ST Therapy, Standard Therapy, Nicotine Patch; Behavioral · Device
Lead sponsor: University of Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: Remote Telemonitoring; Other
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Allergic Asthma
Interventions: Placebo, Omalizumab, Immunotherapy; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Asthma
Interventions: Pictorial Asthma Action Plan, Written Asthma Action Plan; Behavioral
Lead sponsor: West Virginia University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Choroidal Neovascularization
Interventions: Faricimab, Ranibizumab, Sham Procedure; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 52
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more

Conditions: Rheumatoid Arthritis
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 12
States / cities: Anniston, Alabama • Birmingham, Alabama • Peoria, Arizona + 8 more

Conditions: 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Interventions: GVAX Pancreas Vaccine, CRS-207, Chemotherapy, cyclophosphamide; Biological · Drug
Lead sponsor: Aduro Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 20
States / cities: Scottsdale, Arizona • La Jolla, California • San Francisco, California + 16 more

Conditions: Melanoma, Neoplasm Metastasis
Interventions: CC 5013; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 18 more

Search by objective public record fields.

Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients

Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers

Achilles Tendon Lengthening With Traditional vs. Accelerated Rehab

Comparison of Virtual Pelvic Floor Physical Therapy With a Pelvic Floor Trainer in the Treatment of Stress Urinary Incontinence.

A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)

Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus

Revefenacin in Acute Respiratory Insufficiency in COPD

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

Clinical Trial to Assess the Effects of Topical Lotions on Changes in the Skin Microbiome and Associations With Itch

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Adaptation and Initial Evaluation of Transdiagnostic CBT for Anxious and Depressed Smokers

Hypertension Management Using Telemonitoring

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Investigation of the Role of Pictorial Asthma Action Plans to Promote Self-management in Rural Youth With Asthma

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma